ABSTRACT
El virus chikungunya (CHIKV) es un alfavirus cuya infección provoca una enfermedad caracterizada principalmente por fiebre y dolores articulares/musculares. Entre 25-50% de las infecciones se presentan con enfermedad crónica que puede durar de meses a años. El primer brote de CHIKV en Paraguay corresponde al año 2015, siendo el último en el año 2022/2023. Diversos candidatos vacunales contra CHIKV se encuentran en diferentes etapas de desarrollo, e incluso recientemente (noviembre/2023) fue aprobada la primera vacuna contra CHIKV llamada VLA1553 (Ixchiq). Adicionalmente, al menos 30 candidatos vacunales se encuentran en ensayos preclínicos/clínicos. Con la aprobación de la primera vacuna contra CHIKV y la posibilidad de otras que lleguen al mercado prontamente, debido al estado avanzado de otros candidatos vacunales, se abrirá un nuevo escenario en esta enfermedad. Se espera que la introducción de vacunas efectivas genere un avance importante para la prevención de esta enfermedad, disminuyendo los casos agudos y los efectos crónicos de la infección por el virus. En este trabajo de revisión se analiza el avance de las vacunas contra CHIKV, además de examinar los desafíos de vigilancia epidemiológica que plantean la introducción de estas vacunas.
Chikungunya virus (CHIKV) is an alphavirus that causes an illness characterized mainly by fever and joint/muscle pain. Between 25-50% of infections present with chronic diseases that can last from months to years. The first outbreak of CHIKV in Paraguay occurred in 2015, with the last outbreak occurring in 2022/2023. Several vaccine candidates against CHIKV are in different stages of development, and even recently (November/2023), the first vaccine against CHIKV, called VLA1553 (Ixchiq), was approved. In addition, at least 30 vaccine candidates are available for preclinical and clinical trials. With the approval of the first vaccine against CHIKV and the possibility of others coming to the market soon, due to the advanced status of other vaccine candidates, a new scenario will open for this disease. The introduction of effective vaccines is expected to generate an important advance in the prevention of this disease, reducing acute cases and the chronic effects of viral infection. This review analyzes the progress of CHIKV vaccines and examines the epidemiological surveillance challenges posed by the introduction of these vaccines.
ABSTRACT
In response to the COVID-19 pandemic, two mRNA vaccines (Comirnaty and Spikevax) received emergency use authorization from the European Medicines Agency. This case report aimed to report a delayed adverse reaction to the mRNA-1273 vaccine against COVID-19 from a Portuguese vaccination center. A case report was performed with medical observation and reported to the Portuguese Pharmacovigilance System, then investigated based on the WHO-UMC Causality Categories. A 66-year-old female patient with a clinical history of dyslipidemia, essential arterial hypertension, obesity, multinodular goitre and cholecystectomy, who presented delayed large cutaneous hypersensitivity reaction following Spikevax COVID-19 mRNA (mRNA-1273) vaccine administration. Our clinical findings (time and clinical appearance), along with evidence of previously reported histological findings, are strongly suggestive of T-cell-mediated hypersensitivity. There is no contraindication to the inoculation of subsequent doses in patients developing these clinical conditions, and vaccination should continue to be strongly encouraged.
ABSTRACT
Objective:To investigate COVID-19 vaccination status and relevant adverse reactions in patients with psoriasis treated with biological agents, and to explore the effect of COVID-19 vaccination on psoriatic lesions.Methods:Clinical data were collected from 572 psoriasis patients aged 18 - 60 years, who were registered in the management system of psoriasis patients treated with biological agents in the University of Hong Kong-Shenzhen Hospital from May 2019 to June 2021. The COVID-19 vaccination status was investigated by telephone interviews, and the vaccination-related information was obtained by fixed healthcare workers during a fixed time period according to a predesigned questionnaire. Measurement data were compared between two groups by using t test, and enumeration data were compared by using chi-square test or Fisher′s exact test. Results:The COVID-19 vaccination coverage rate was 43.13% (226 cases) among the 524 patients who completed the telephone interview, and was significantly lower in the biological agent treatment group (30.79%, 105/341) than in the traditional drug treatment group (66.12%, 121/183; χ2 = 60.60, P < 0.001) . The main reason for not being vaccinated was patients′ fear of vaccine safety (49.66%, 148/298) , followed by doctors′ not recommending (26.51%, 79/298) . In the biological agent treatment group after vaccination, the exacerbation of psoriatic lesions was more common in patients receiving prolonged-interval treatment (42.86%, 6/14) compared with those receiving regular treatment (4.40%, 4/91; Fisher′s exact test, P < 0.001) . Skin lesions were severely aggravated in two patients after COVID-19 vaccination, who ever experienced allergic reactions and whose skin lesions did not completely subside after the treatment with biological agents. Conclusions:The COVID-19 vaccination coverage rate was relatively low in the psoriasis patients treated with biological agents, and no serious adverse reaction was observed after vaccination. Prolonged-interval treatment due to COVID-19 vaccination ran the risk of exacerbation of skin lesions.
ABSTRACT
Dear colleagues: The Organizing Committee of the V International Congress on Pharmacology of Vaccines (VacciPharma 2020) organized by the Cuban Society of Pharmacology, BioCubaFarma and the International Union of Basic and Clinical Pharmacology (IUPHAR) would like to invite you to participate in this important event, scheduled for June 14 to 18, 2020 at the Convention Centre of the Melia Marina Varadero Hotel, Varadero Beach, Matanzas, Cuba. The Congress will be formed by different workshops and symposia such as: Meningococcal and Gonococcal vaccines Pneumococcal vaccines Pertussis and combined vaccines Enteric vaccines Leptospira vaccines Viral vaccines Animal models in vaccine development, QC and 3Rs Vaccine technology and bioprocess Vaccine technology transfers Patent, business and international cooperation VacciPharma 2020 is sponsored by: Cuban Society of Pharmacology (SCF) International Union of Basic and Clinical Pharmacology (IUPHAR) Latin-American Association of Pharmacology (ALF) PAHO / WHO BioCubaFarma National research centers: Finlay Vaccine Institute (IFV); Center of Genetic Engineering and Biotechnology (CIGB); Center of Molecular Immunology (CIM); Center for Control of Drugs, Equipment and Medical Devices (CECMED); National Center for Animal and Plant Health (CENSA); Tropical Medicine Institute Pedro Kourí (IPK); National Center for Biopreparations (BioCEN); Center for Drug Research and Development (CIDEM); Center for Clinical Trials (CENCEC); among others International Manufacturers and Companies The key objectives of the Congress are: To provide a progressive state-of-the-art report for scientists, manufacturers, governmental authorities and healthcare workers, who need to be updated about the latest scientific developments for human vaccines, including basic science, product development, market introduction, immunization programs and epidemiological surveillance. To promote the scientific collaboration among experts and institutions through the experience exchange, the presentation of results and the discussion on the conference topics. To accelerate progress in the development of vaccines and the acceptance and introduction of new methods and technologies. Opening lectures, oral presentations and posters will provide you the opportunity to be involved in a high quality congress to discuss about the progress in the field of vaccinology and pharmacology sciences. Deadline for registration and abstract submission: April 15th, 2020 Further information can be found at the VacciPharma 2020 Website: www.immunovaccipharma.com
Subject(s)
Animals , Pharmacology , Bacterial Vaccines , Viral Vaccines , Technology, Pharmaceutical/methods , Models, Animal , Congress , CubaABSTRACT
Objective@#To evaluate the post-marketing safety profiles of the inactivated enterovirus type 71 (EV-A71) vaccine (Vero cell) after routine inoculation.@*Methods@#Eleven cities of Zhejiang Province, Fengtai district of Beijing, Qinnan district, two counties as Pingle and Pingguo of Guangxi Zhuang Autonomous Region, and Dongtai city of Jiangsu Province were selected as the field sites. A total of 45 239 subjects were enrolled in this study from children who seeked the vaccination of EV-A71 vaccine during the period from July, 2016 to June, 2018. Different sampling method were adopted in different sites. All vaccinated children were invited to participate in the study in Fengtai and Dongtai, however, systematic sampling method were adopted in other sites. Active surveillance was conducted and information about adverse reactions (ARs) occurred in 30 min, 3 d and 30 d following each dose of EV-A71 immunization was collected by field observation, phone-call or face-to-face interview. The incidence of ARs in different types, symptoms and grades were described.@*Results@#In total, there were 45 239 children who received 71 243 doses EV-A71 vaccine. The overall incidence of ARs was 1.079% (769 doses), with the highest incidence of 1.182% (177/14 973) in 5-11 month group and the lowest incidence of 0.849% (18/2 119) in ≥ 36 month group among different age groups. There was a higher incidence in solicited ARs, which was 1.047% (746 doses). The incidences of grade 1 and grade 2 ARs were also higher, which were 0.404% (288 doses) and 0.554% (395 doses), respectively. No grade 4 ARs occurred. The doses of the first and the second vaccination was 40 736 and 30 507, respectively, and the incidences of ARs were 1.281% (522 doses) and 0.810% (247 doses). Also, the incidences of ARs were 0.091% (37 doses) and 0.043% (13 doses) in local, and 1.168% (476 doses) and 0.760% (232 doses) in system. The symptoms of ARs after the two doses of vaccination were basically the same. Redness at the injection site was the most common local ARs after each dose vaccination, with doses of 24 and 11, while fever was the most common systemic ARs, with doses of 362 and 190. Moreover, ARs mainly occurred in 30 min to 3 d after each dose vaccination, with incidence of 1.016% (414 doses) and 0.698% (213 doses) in the first and second dose, respectively.@*Conclusion@#The ARs had a low incidence after vaccination in children and most were mild or moderate. EV-A71 vaccine with good safety is suitable for inoculation in a large scale.
ABSTRACT
As a pathogen causing many infectious diseases, Flavivirus genus arborvirus has caused public health emergencies worldwide and posed a serious threat to human health. Attenuated vaccine is the most effective vaccine type against Flavivirus genus arborvirus. The attenuated vaccines against yellow fever virus and Japanese encephalitis virus obtained by consecutive cell passages play an important role in preventing viral infections. Recently, reverse genetics technique has been used to modify the flavivirus genome to obtain the attenuated phenotype, and this technique has made significant progress in the development of Flavivirus genus arbovirus vaccines. This review summarizes the history and the current status of attenuated vaccine of Flavivirus genus arborvirus.
ABSTRACT
Enhancing national biodefense science and technology capacity is the basis of and key to biosafety and biosecurity .A further improved biodefense capability is required for the military to defend national sovereignty and territorial integrity , safeguard national interests overseas , and carry out military operations other than war .Currently , global biodefense technology is progressing rapidly .Research on detection and diagnosis products for biological threats focuses on novel, fast, portable, and remote identification technologies .As for biodefense vaccine development , research of vaccines for emerging viruses, bacteria, toxins, and malaria has made positive progress .In biodefense pharmaceutical research , new anti-influenza drugs , anti-Ebola drugs , anti-Marburg virus drugs , and new antibiotics for anthrax and plague keep emerging.In the future, China should give priority to research on biosurveillance and early warning , biodefense product transformation, and all-spectrum biodefense system construction .
ABSTRACT
Organoid is an in vitro multicellular form mimicking in vivo organ. Its similarity to human organ including cellular organization, molecular expression patterns, as well as genetic signatures enables to study the characteristics of infectious agents and host-pathogen interaction. For the features of organoid, this system also can be potentially used to cultivate currently uncultivable viruses of vaccine candidates. This paper will briefly describe problems in the current culture system for virus production and the possibility of organoid as culture system for viral vaccine and their current limitations that should be solved to meet the goal.
Subject(s)
Humans , Host-Pathogen Interactions , In Vitro Techniques , Organoids , Viral Vaccines , Virus CultivationABSTRACT
As proteínas E7 (HPV), p24 (HIV) e gD (HSV) são exclusivamente expressas por células infectadas ou tumorais e, por isso, são utilizadas como alvos para vacinas com características terapêuticas. Foram desenvolvidas duas vacinas de DNA capazes de expressar as três proteínas virais por meio de um vetor de expressão bicistrônico baseado na sequência IRES. As vacinas, denominadas pIRES I e pIRES II, diferem entre si por transportarem os genes que codificam as proteínas E7 do HPV-16 e p24 do HIV fusionadas à proteína gD do HSV-1 em ordem inversa. Células COS-7 transfectadas com os plasmídeos vacinais expressaram as proteínas alvo, como determinado por imunofluorecência com anticorpos específicos para as proteínas gD, p24 e E7. As vacinas foram testadas em modelo murino quanto à capacidade de gerar anticorpos e células T CD8+ específicas. Observamos que animais vacinados desenvolveram baixas taxas de anticorpos contra gD, p24 e E7. Em contrapartida, demonstramos a indução de células T CD8+ específicas para os três antígenos testados. Os plasmídeos vacinais foram capazes de proteger camundongos inoculados com células tumorais TC-1 (que expressam a proteína E7 do HPV-16), embora apresentando diferentes níveis de proteção em ensaios profiláticos e terapêuticos. As formulações foram testadas em relação à capacidade de proteger animais frente a desafio com o HSV-1 sendo que apenas um deles gerou efeito protetor. Em conclusão, os resultados demonstram que vacinas voltadas para o controle terapêutico de infecções ou processos tumorais associados aos vírus HPV, HIV e HSV representam uma meta viável e promissora
The proteins E7 (HPV), p24 (HIV) and gD (HSV) are exclusively expressed by infected cells or tumors and therefore are used as targets for vaccines with therapeutic characteristics. We developed two DNA vaccines capable of expressing these three viral proteins using a bicistronic expression vector based on IRES sequence. The plasmid vaccines, named pIRES I and pIRES II, differ by carrying the genes that encode proteins of HPV-16 E7 and p24 fused to the HIV protein gD of HSV-1 in reverse order. Transfected COS-7 cells expressed the target proteins, as determined by immunofluorescence with specific antibodies for gD, p24 and E7. The vaccines were tested in mice for their ability to generate antibodies and specific CD8+ T cells. We observed that vaccinated animals developed low levels of antibodies against gD, E7 and p24. In contrast, we demonstrate the induction of specific CD8+ T cells for the three antigens. The plasmid vaccines were able to protect mice inoculated with TC-1 tumor cells (which express the E7 protein of HPV-16), although with different levels of protection in prophylactic and therapeutic trials. The formulations were tested for ability to protect animals against challenge with HSV-1 and only one of them generated a protective effect. In conclusion, the results show that vaccines directed to therapeutic control of infections or tumor process associated with HPV, HSV or HIV represents a promising and viable goal
Subject(s)
Animals , Female , Adjuvants, Immunologic , AIDS Vaccines , Cytokines , Granulocyte-Macrophage Colony-Stimulating Factor , Herpesvirus 1, Human , HIV-1 , Mice, Inbred BALB C , Vaccines, DNA , Viral Envelope ProteinsABSTRACT
Objective To study the effectiveness of vaccinia vaccination rabbit inflammatory skin extracts on blood homocysteine(Hcy) and insulin-like growth factor-1(IGF-1) in patients with diabetic peripheral neuropathy. Methods 100 patients with diabetic peripheral neuropathy were randomly divided into the two groups,the observa-tion group(n=50 cases) and the control group(n=50 cases).The observation group was treated through vaccinia vaccination rabbit inflammatory skin extracts, while the control group was treated through mecobalamin.They were treated for 15 days.Median nerve,peroneal motor nerve conduction velocity (MCV) and sensory nerve conduction velocity ( SCV) were determined before and after treatment.Blood IGF-1 and Hcy were detected.Results TSS were significantly lowered after treatment (t=9.772,13.624,all P<0.01).Compared with the control group,the observa-tion group was significantly decreased (t=3.925,P<0.05).After treatment,the median nerve,peroneal nerve MCV and SCV were significantly increased (t=5.103,3.019,4.998,2.928,5.128,3.112,5.286,3.118,all P<0.05). Compared with the control group,theobservation group was observed to increase more significantly(t=2.826,2.743, 3.268,3.096,all P<0.05).After treatment,serum IGF-1 were significantly elevated,and compared with the control group after treatment,post-treatment observation group increased more significantly(t=4.179,P<0.05).After treat-ment plasma Hcy were significantly lower than that of the control group after treatment,the observation group after treatment significantly decreased(t=3.165,P<0.05).Conclusion Vaccinia vaccination rabbit inflammatory skin extracts can improve blood Hcy and IGF-1 in patients with diabetic peripheral neuropathy.
ABSTRACT
OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses. METHODS: Antibody levels against hepatitis B, rubella, measles and mumps vaccine antigens were evaluated in 33 children after completing chemotherapy (before and after vaccine booster doses) and the results were compared to the data of 33 healthy children matched for gender, age and social class. RESULTS: After chemotherapy, 75.9%, 67.9%, 59.3% and 51.7% of the patients showed low antibody titers that would be unlikely to protect against exposure to measles, rubella, hepatitis B and mumps, respectively. After receiving a vaccine booster dose for these antigens the patients had high antibody levels consistent with potential protection against measles, mumps and hepatitis B, but not against rubella. CONCLUSION: Extra doses of measles-mumps-rubella plus hepatitis B vaccines are recommended in acute lymphoblastic leukemia patients submitted to treatment after hematologic recovery. After this, viral vaccine antibody levels should be verified to define the individual's protective status.
Subject(s)
Humans , Male , Female , Child , Viral Vaccines , Leukemia, Lymphoid , Antineoplastic Combined Chemotherapy Protocols , Child , ImmunizationABSTRACT
Objective To understand the nucleotide and amino acid differences of glycoprotein gene (G gene) between isolated rabies viruses in Henan Province and rabies vaccine strains used for human and animals. Methods G gene sequences of nine rabies viruses isolated from dogs in Xinyang city of Henan Province in December 2006 were amplified by reverse transcriptase (RT)-heminestedpolymerase chain reaction (PCR), and then were cloned and sequenced. The phylogenetic trees were constructed for analyzing the genetic characteristics of these rabies viruses. Results The homology of G gene among the nine isolates from Henan Province was 97.6% - 98.9% at nucleotide level and 99.2%-99.8% at amino acid level. The similarities between these isolates and CTN vaccine strain were 85.6%-93.0% and 91.9%-92.9% at nucleotide and amino acid level, respectively, which were higher than those between these isolates and other vaccine strains (80.4% - 83.3% and 87.7% - 92.5% at nucleotide and amino acid level, respectively). The nine isolates had several amino acid substitutions when compared to other genotype 1 rabies virus strains. Conclusions The nine rabies viruses strains isolated from Henan Province all belong to genotype 1. CTN may be an effective vaccine for preventing rabies in Henan Province.
ABSTRACT
The mode of transmission and epidemiological approach for hepatitis A and B are different. However, both are preventable with vaccines whose efficacy and long lasting protection has been demonstrated. This review describes the secular tendency of both infections in Chile, their risk factors that have contributed to their persistence in the country and the interventions that have been carried out to reduce the disease burden. Although the vaccine for hepatitis B was incorporated to the immunization program in 2005, the vaccine for hepatitis A persists in the list of interventions that must be assumed with priority by the Ministry of Health. If Chilean health authorities pretend to reach the enteric disease indicators of developed countries, they must accelerate the epidemiological transition towards the elimination of hepatitis A.
Subject(s)
Female , Humans , Male , Hepatitis A Vaccines/administration & dosage , Hepatitis A/prevention & control , Hepatitis B Vaccines/administration & dosage , Hepatitis B/prevention & control , Chile/epidemiology , Hepatitis A/epidemiology , Hepatitis A/etiology , Hepatitis B/epidemiology , Hepatitis B/etiologyABSTRACT
Objective: To investigate the difference in distribution of subtypes of Human papilloma virus (HPV) between cervical cancer patients and normal controls of Xinjiang Uighur women and analyze the HPV spectrum in Xinjiang Uighur women suffered from cervical cancer. Methods: Three hundred and thirty Uighur women with cervical cancer and one hundred normal healthy women were recruited in this study. Flow-through hybridization and gene chip (HybriMax) technology was used to detect the twenty one subtypes of HPV. Results: (1) The positive rate of HPV infection including simple infection and multiple infection was 85.15% (281/300) and 7.0% (7/100) in cervical cancer group and control group, respectively. The positive rate of HPV16 infection was 94.31% indicating it was the most common infection in HPV-positive cervical cancer patients. The infection rate was 5.34% for HPV18, 3.91% for HPV68, 2.49% for HPV45, 2.49% for HPV58, 2.14% for HPV39, 1.07% for HPV31, 1.07 for HPV56, and 0.36 for HPV59. There was significant difference in the total infection rate and the HPV16 infection rate between cervical cancer patients and controls (P0.05 ). Although the positive rate of multiple infection of HPV tended to increase but the difference was not significant. Conclusion: HPV16 infection was the most common in cervical cancer patients and normal controls of Xinjiang Uighur women. The next most common types of HPV were HPV18 and HPV68. Xinjiang Uighur women had the relatively higher risk of suffering HPV68 infection indicating the specificity of HPV infection in Uighur women.